Yvonne Greenstreet, Alnylam CEO (via Alnylam)

Al­ny­lam boasts PhII win in kid­ney dis­ease cor­ner­stone of Re­gen­eron R&D block­buster deal

A drug at the heart of the $1 bil­lion-plus Al­ny­lam and Re­gen­eron col­lab­o­ra­tion ce­ment­ed three years ago has some new ef­fi­ca­cy da­ta to show off.

The RNAi biotech once helmed by John Maraganore re­port­ed pos­i­tive topline da­ta Thurs­day for its in­ves­ti­ga­tion­al cem­disir­an, an RNAi drug tar­get­ing the C5 com­po­nent of the path­way that both Al­ny­lam and Re­gen­eron are work­ing on in IgAN, or im­munoglob­u­lin A nephropa­thy. The da­ta come out of a Phase II de­scrip­tive tri­al, with no sta­tis­ti­cal hy­poth­e­sis test­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.